Understanding Carvykti®

Carvykti^® (ciltacabtagene autoleucel, or “cilta-cel” for short) is a customized immunotherapy approved by the FDA for the treatment of patients with relapsed or refractory myeloma after 4 or more prior lines of therapy. Clinical trial data show promising data after 1 to 3 prior lines of therapy. Carvykti uses a patient’s own T cells, which are collected and genetically modified, then infused back into the patient to bind to a protein on myeloma cells, destroy those cells, thereby eliminating the myeloma cells.